Jan Yperman Ziekenhuis
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Jan Yperman Ziekenhuis in Ieper, the cardiology research program focuses on cardiovascular diseases, especially atrial fibrillation and coronary artery conditions. The trials are aimed at understanding how to improve everyday treatment choices, with attention to both safety and effectiveness in patients who need ongoing heart care.
- Studies in atrial fibrillation and related antithrombotic care
- Research on acute coronary syndrome and chronic coronary syndrome
- Evaluation of treatment strategies after coronary procedures to balance bleeding and ischemic risk
This work reflects a practical interest in refining cardiology treatments for patients with complex heart disease, especially where prevention of complications is a key goal.
Neoplasms
The site also contributes to oncology research within the broader field of neoplasms, with a focus on breast neoplasms. These studies are designed to assess whether new treatment approaches can improve outcomes for people with early-stage disease and a higher chance of recurrence.
- Research in breast cancer care for patients at increased risk of recurrence
- Comparison of a new endocrine treatment approach with standard therapy
- Efforts to improve long-term disease control after initial treatment
At Jan Yperman Ziekenhuis, this area of research supports the search for better cancer treatments that may offer stronger protection against relapse while remaining practical for routine care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 58 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 54 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1AstraZeneca AB2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Jan Yperman Ziekenhuis
lock Showing 1 of 21 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1/2, randomized, dose-finding/dose-confirmation study to evaluate the reactogenicity, safety and immunogenicity of mRNA-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults | GlaxoSmithKline Biologicals | Phase I/II | Not Recruiting | Apr 2023 | Jul 2024 |
IMP list
lock Showing 1 of 58 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238) | 3 | Unknown | 2023-04-27 | 2025-10-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.